Latest paediatric equipment Tenders | Government paediatric equipment Tenders

CTN :45004704

27 May, 2026 28.76 Lacs

Darjeeling - West Bengal

Tender For bid to ras bid to ras bid to ras bid to ras corrigendum : supply of drug and pharmaceutical items - sitagliptin 50mg tab + metformin 1000mg tab , tab sodium valproate 500mg cr (sodium valproate 333mg + valproic acid 145mg) , tacrolimus 0.5mg tab , tacrolimus 1mg tab , tacrolimus 2mg tab , tamsulin 0.4mg + dutasteride 5mg tab , taurine 500mg + acetylcystine 150mg tab , telmisartan 20mg tab , telmisartan 40mg + amlodipine 5mg tab , telmisartan 40mg +chlorthalidone 12.5mg tab , telmisartan 40mg + hydrochlorthiazide 12.5mg tab , thyroxine 50mcg tab , tofacitinib 11mg tab , torsemide 10mg tab , torsemide 20mg tab , ursodexycholic acid 300mg tab (udiliv ) , vericiguat 2.5mg tab , vildagliptin 50mg tab , vit a, d, e, c, b1, b12, folic acid, biotin (menopace) tab , cetrizine 5mg + paracetamol 325mg + phenylephrine hcl 5mg (cold plus) tab , fungal diastace 100mg + papain 60mg + activated charcol 75 mg (unienzyme) tab , inj darbepoetin 60mg , inj erythropoietin recombinant human 2000 iu , inj erythropoietin recombinant human 6000 iu , inj human insulin glargine 300iu/ml, 3ml cartridge , inj rabipur vaccine 1ml (cell culture rabies vaccine vial of 1 ml ) , human insulin analogue aspart premix 50 per insulin / 50 per insulin protamine aspart suspension 100 iu/ml (monocomponent insulin, recombinant dna origin) 3 ml pfp / pfs (novomix 50) inj , influenza vaccine (vaxigrip) , insulin lispro biphasic 50% (50% insulin lispro and 50% insuline lispro protamine suspension 100iu/ml,3ml cart) humalog mix 50 3ml cart , syp sucralfate 1gm/5ml bott of 200ml , syp antacid gel 170ml (digene gel) , bromhexine (2mg) + guaifenesin (50mg) + menthol (1mg) + terbutaline (1.25mg) syrup , bromhexine 100ml syp , cremaffin (liquid paraffin 1.25mg+ magnesium hydroxide 3.75mg+ sodium picosulphate 3.3mg) 170ml syp , guaiphenesin ip 100mg + dextramethorphan 10mg + phenylepherine 5mg chlorpheniramine 4mg each 5ml sugar free syp bott of 100ml , ketoconazole (2% w/v) lotion 75ml , mometasone 0.1% tube of 10 gm oint , mupirocin 2% tube of 5 gm oint , oestrogen cream (concentration 0.06% to 0.1% w/w) (tube of 15 to 50 gm) , oin clobetasol + salicylic acid (dipsalic ) , tacrolimus 0.1 % ointment, tube of 10 gm , tacrolimus oint( 0.03% ) 20 gm tube , (linseed oil + diclofenac+methyl salicylate + menthol gel) , amorolfine 5% nail lacquer, bott of 2.5ml , calamine lotion 100ml , chlorhexidine mouth wash 2% bott of 100 ml , clobetasol 0.05%w/w + salicylic acid 3.5% w/w cream, tube of 20gm , diclofenac spray bottle of 40 gm , fourderm cream chlorhexidine gluconate (0.20%), clobetasol topical (0.05%), miconazole topical (2%), neomycin topical (0.5%) 30 gm , delivery system for salmeterol + fluticasone rotacaps with pin puncture , formoterol (6mcg) + budesonide (400mcg) rotacap , inh formoterol 6 mcg+tiotropium 9mcg mdi (duova) , inh indacaterol 110 mcg + glycopyrrolate 50 mcg , inh salmeterol 25mcg + fluticasone 125mcg 120 mdi (seroflow) , beclomethasone dipropionate 50 mcg+levosalbutamol 50 mcg mdi (aerocort inhaler) , mdi levosalbutamol 50 mcg 200 md , nasal spray calcitonin 200iu , salbutamol 200 mdi (each metered dose supplies 100mcg of salbutamol) mdi , tiotropium (18mcg) rotacap , tiotropium bromide 9 mcg, 120 metered doses/unit, inhalerotacap

CTN :45146882

25 May, 2026 1.00 Crore

Alappuzha - Kerala

Tender For empanelment for the supply of cathlab items on running contract basis under kasp and other schemes of this hospital - coronary stents, des,everolimus,fda/dcgi/ce approved platinum chromium platform,polyvinylidene fluride-hexafluropropyline pvdf-hfp polymer-stent lengths8,12,16,24,28,32. stent diameter 2.25*,2.50,2.75,3.00,3.50,4.00.struct thickness 81/86 microns.nominal pressure - 11 atm,rated burst pressure 16-18 atm, des,everolimus,fda/ approved platinum chromium platform,polyvinylidene fluoride-hexafluropropylene(pvdf-hfp)polymer, des,everolimus,fda/dcgi/ce/ approved platinum chromium platform,bioabsorbable polymer plga, everolimus eluting platinum chromium stent system, des, everolimus, l 605 cobalt chromium with hybrid cell design , strut thickness- 65microns, polymer- plga diameter- 2.25, 2.5, 2.75, 3.0, 3.5,4. length- 10,13,15,18,20,24, 28, 32,36,40, 42, 44, des, everolimus, cobalt chromium strut thickness - 63 microns . diameter- 2.25,2.5,2.75,3,3.5,4. length- 8,10,13,15,18,20,24,28,32,36,40,42,44. elutes 80% of drugs along with re plga polymer in the first 20 days, dcgi approved everolimus drug eluting 65 micron strut thickness with 3 micron plla&plga. a unique proprietory coating technology basedbiodegradable polymer stent with open cell designed and flexia finished technology based cobalt chromium l605 stent.a designed for optimal strength, flexibility ,trackablity ,side branch supported,bifurcation supported and high radial strength and optimal radiopacity and excellent vessel supported stent with revers alternative link design(ral) stent, with length from 8 mm to 52 mm and diameter from 2.25 mm to 4.50 mm, ce approved everolimus eluting coronary stent system struts/cells shows a wavy pattern and are not straight with outerradius of 0.1725mm. the cell angle is between 42 degree to 57 degree with respect to different diameter. the cells are connected by link (mid to mid pattern) with a radius of 0.2700mm. these values have been validated for lower stent profile, uniform expansion, side branch access, good trackability & strong radial support. components - drug: everolimus, stent platform: cobalt chromium l605 alloy, polymer: biodegradable, catheter: ptca rapid exchange semi-compliant stent delivery catheter. drug concentration: 1.2 microgram/mm2 of stent surface area. stent diameter(mm): 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00 & 4.50 & stent length (mm): 8, 13, 16, 20, 24, 28, 32, 36, 40, 43, 47 platinum-iridium radiopaque markers are precisely placed within the balloon cones for accurate stent positioning, also the difference between stent edge to marker is 0.5mm (atboth sides, proximal & distal) which prevents the dogboning during the angioplasty., ce approved sirolimus eluting coronary stent system struts/cells shows a wavy pattern and are not straight with outerradius of 0.1725mm. the cell angle is between 42 degree to 57 degree with respect to different diameter. the cells are connected by link (mid to mid pattern) with a radius of 0.2700mm. these values have been validated for lower stent profile, uniform expansion, side branch access, good trackability & strong radial support. components - drug: everolimus, stent platform: cobalt chromium l605 alloy, polymer: biodegradable, catheter: ptca rapid exchange semi-compliant stent delivery catheter. drug concentration: 1.2 microgram/mm2 of stent surface area. stent diameter(mm): 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00 & 4.50 & stent length (mm): 8, 13, 16, 20, 24, 28, 32, 36, 40, 43, 47 platinum-iridium radiopaque markers are precisely placed within the balloon cones for accurate stent positioning, also the difference between stent edge to marker is 0.5mm (atboth sides, proximal & distal) which prevents the dogboning during the angioplasty., only dcgi approved everolimus eluting coronary stent system struts/cells shows a wavy pattern and are not straight with outerradius of 0.1725mm. the cell angle is between 42 degree to 57 deg

Central Government/Public Sector

CTN :45254443

03 Jun, 2026 NA

Perambur - Tamil Nadu

Tender For srphc82281240-coronary drug eluting stents with (1) stent on cobalt chromium alloy or platinum chromium alloy. (2) stent with coating of polymer carrier for active drug ( sirolimus, everolimus or zotarolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.5mm to 4mm and length of the stent should be 12mm to 48mm. (4) the strut thickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval shouldbe enclosed in the tender bid. (9) the long term efficacy and safety of the stent in terms of target vessel revascularisation (tvr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals. (10) the documents related to the efficacy and safety of the stent should be only for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent toa major government institute.[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]

Central Government/Public Sector

CTN :45254856

01 Jun, 2026 NA

Perambur - Tamil Nadu

Tender For srphc82281215-coronary drug eluting stents (1) with single wire design with cobalt alloy shell and platinum iridium core (2) stent with coating of biolinx polymer carrier for active drug zotarolimus shown to be effective in preventing neo-intimal hyperplasia (3) stent diameter should be from 2 mm to 5mm and length of the stent from 8 mm to 38 mm. (4) the strut should be round with thickness ranging from 81 to 91 microns (5) stent delivery system should be monorail (single operator exchange or rapidexchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) five years efficacy and safety of the stent in terms of target vessel revascularisation (tvr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals.(10) the documents pertaining to the efficacy and safety of the stent should be enclosed for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute. ]

Central Government/Public Sector

CTN :45227572

15 Jun, 2026 NA

Perambur - Tamil Nadu

Tender For srphc82281210-coronary drug eluting stents (1) single wire technology on cobalt based alloy platform (2) stent with coating of biolinx polymer carrier for active drug zotarolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.25 mm to 4 mm and length of the stent from 12mm to 38 mm. (4) the strut thickness should be 81 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) five years long term efficacy and safety of the stent in terms of target vesselrevascularisation (tvr) and in-situ thrombosis (ist) should be documented / published inpeer reviewed scientific journals.(10) the documents pertaining to the efficacy and safety of the stent should be enclosed for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute.[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]

Central Government/Public Sector

CTN :45227573

15 Jun, 2026 NA

Perambur - Tamil Nadu

Tender For srphc82281275-des-abbreviated dapt long -coronary drug eluting stents with (1) platinum chromium alloy (2) coating of bioabsorbable polymer carrier for activedrug everolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.5mm to 4mm. the length of the stent should be from 12mm to 48 mm. (4) the strut thickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) the long term efficacy and safety of the stent, the rates of in-stent restenosis (isr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals. (10) safety of abbreviated (three month) dual antiplatelet therapy for high bleeding risk patients should be documented in peer reviewed journals. (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute. bis standards for the drug eluting stent are not available. (reference:bis catalogue ).[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]

Central Government/Public Sector

CTN :45227584

16 Jun, 2026 NA

Perambur - Tamil Nadu

Tender For srphc82281225-coronary drug eluting stents with (1) cobalt chromium alloy (2) coating of bioabsorbable polymer carrier with abluminal and gradient coating foractive drug shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.5mm to 4mm . the length of the stent should be from 12mm to 38 mm. (4) the strut thickness should be 91 micron or less. (5) stent delivery system should bemonorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) the long term efficacy and safety of the stent, the rates of in-stent restenosis (isr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals. (10) safety of abbreviated (one month) dual antiplatelet therapy for high bleedingrisk patients should be documented in peer reviewed journals. (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute. bis standards for the drug eluting stent are not available. (reference:bis catalogue ).[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]

Central Government/Public Sector

CTN :45227585

16 Jun, 2026 NA

Perambur - Tamil Nadu

Tender For srphc82281280-des-pt/cr : coronary drug eluting stents (1) on platinum chromium platform (2) stent with coating of polymer carrier for active drug everolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter shouldbe from 2.5mm to 4mm and length of the stent from 12mm to 38 mm. (4) the strutthickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved bydcgi . the copy of dcgi approval should be enclosed in the tender bid. (9) the long termefficacy and safety of the stent in terms of target vessel revascularisation (tvr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals.(10) the documents pertaining to the efficacy and safety of the stent should be enclosed for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute.[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]

Central Government/Public Sector

CTN :45227589

17 Jun, 2026 NA

Perambur - Tamil Nadu

Tender For srphc82281246-coronary drug eluting stents with (1) cobalt chromium alloy and with coating of polymer carrier for active drug everolimus. (2) crossing profile less than or equal to 0.0425 inch and mid marker stent placement. (3) stent diameter should be from 2.0 mm to 4 mm and length of the stent from 8 mm to 38 mm. (4) the strut thickness should be 81 micron. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guidingcatheter (7) stent design should be open cell type. (8) stent should be approved by dcgi.the copy of dcgi approval should be enclosed in the tender bid. (9) the long term efficacy and safety of the stent in terms of target vessel revascularisation (tvr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals.(10) the documents pertaining to the efficacy and safety of the stent should be enclosed in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute.[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]